PRESS RELEASE | National Institutes of Health approves next round of ASSURE-19 funding under the RADx ‘Next’ program

Oceanit Laboratories received approval from NIH for next round funding under the RADx initiative, receiving an additional $250,000 for further development of the ASSURE-19 rapid Covid-19 saliva test. With this latest round of funding, Oceanit will have access to additional NIH R&D resources through the RADx network of core partners, which can help to expedite moving ASSURE-19 to market.

HNL reef runway Oahu Hawaii

The Aloha Protocol for a safer reopening with ASSURE-19

As Oceanit moves ahead with in-vitro and in-vivo testing for the ASSURE-19 rapid point-of-need test kits, Hawaii is seeing high, sustained counts for new covid-19 cases each day. Check out the latest articles and coverage of ASSURE-19 from the Washington Post, Hawaii Public Radio, and Honolulu Star Advertiser.

Press Release | AUG 20: NIH Funding and Moving to Trials

Oceanit Laboratories’ ASSURE-19 rapid point-of-need COVID-19 test has been selected for continued support by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to fill the nation’s critical need for rapid, simple, and affordable COVID-19 testing. 

Honolulu Star Advertiser: Hawaii coronavirus saliva test could help turn pandemic’s tide

CEO Dr. Patrick Sullivan spoke to The Star Advertiser’s Mindy Pennybacker about how the ASSURE-19 rapid “spit test” can help to protect lives and responsibly help to restore the economy and the unique ‘capture and detector molecule’ approach to COVID-19 respiratory disease detection. Click to read more.

Copyright 2020 Oceanit Laboratories, Inc.